Bedrijfsoverzicht
ENDRA Life Sciences Inc. is a specialized entity dedicated to advancing the capabilities of clinical diagnostic ultrasound through proprietary technological development. The company focuses on creating thermo-acoustic enhanced ultrasound technology, which utilizes a pulsed energy source comprising radio frequency to transmit energy deep into tissue for improved diagnostic imaging. Operating within the Healthcare sector and specifically the Diagnostics & Research industry, the firm aims to provide enhanced visualization tools for medical professionals. The company currently holds a market capitalization of $6.13M, while specific figures for annual revenue and employee count are not disclosed in public financial records. These valuation metrics suggest that ENDRA Life Sciences Inc. operates as a micro-cap entity with limited market penetration, indicating a high-risk, early-stage profile typical of companies developing novel medical technologies without established commercial revenue streams.
Financiële gezondheid
The company reported a net income of $-7,027,410 and an EBITDA of $-5,719,056 over the trailing twelve months, reflecting a significant operational deficit. The gap between revenue and net income is substantial, revealing a cost structure where operating expenses or other deductions far exceed any generated revenue, resulting in a net loss that consumes the entire income statement. Free cash flow stands at $-6,020,649, which indicates that the company is burning through its liquidity reserves to fund operations and technology development rather than generating cash from business activities. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, signaling that the company has not yet achieved profitability or positive contribution margins from its sales. On the balance sheet, the company holds $762,365 in cash against $492,352 in debt, resulting in a debt-to-equity ratio of 21.78 which suggests a leveraged position relative to its equity base despite the positive cash balance. The current ratio is 1.29, indicating that the company possesses sufficient current assets to cover its short-term liabilities, though the margin of safety is relatively narrow given the negative earnings environment. Return on Equity is -291.6% and Return on Assets is -86.7%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently to generate returns.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is not available (N/A) due to negative earnings, while the forward P/E is listed as -1.24, implying that the market prices the stock based on expected future earnings that are currently projected to remain negative or that the calculation methodology accounts for the loss-making status. The price-to-book ratio is 22.66, which indicates that the market values the company at a significant premium over its net asset book value, a common characteristic of biotech firms where intellectual property and future potential are valued higher than tangible assets. Since revenue is N/A, the price-to-sales ratio is unavailable, and the EV/EBITDA stands at -1.02, suggesting that the enterprise value is priced relative to negative earnings, a metric often used to assess the cost of acquiring a distressed or pre-revenue company. The stock has traded between a 52-week high of $11.96 and a 52-week low of $2.90, providing a wide trading range that reflects high investor sentiment volatility. The beta value of -0.22 is highly unusual for equities and indicates a negative correlation with the broader market, meaning the stock price tends to move inversely to the market index, although this anomaly requires careful interpretation regarding systemic risk.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet generated positive revenue to establish a growth trajectory. Consequently, it is impossible to calculate whether earnings are growing faster or slower than revenue because no positive baseline exists for comparison. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning it does not distribute cash to shareholders but instead retains all available funds to reinvest into its R&D initiatives and technology development. This reinvestment strategy is typical for development-stage companies that prioritize building their product pipeline over providing income to investors. The overall growth and income profile of ENDRA Life Sciences Inc. is defined by a complete lack of historical earnings growth and a total absence of dividend income, characterizing the asset purely as a speculative investment in future technological breakthroughs rather than a value or income-generating instrument.